Related Experiment Videos
Secretory phospholipases A2 activate selective functions in human eosinophils.
Massimo Triggiani1, Francescopaolo Granata, Barbara Balestrieri
1Division of Clinical Immunology and Allergy, University of Naples Federico II, Naples, Italy. triggiani@unina.it
Journal of Immunology (Baltimore, Md. : 1950)
|March 11, 2003
Summary
Secretory phospholipases A2 (sPLA2s) activate human eosinophils, promoting inflammatory responses. This activation occurs independently of sPLA2 enzymatic activity, highlighting a novel signaling pathway in inflammation.
Area of Science:
- Biochemistry
- Immunology
- Cell Biology
Background:
- Secretory phospholipases A2 (sPLA2s) are implicated in systemic inflammatory diseases and accumulate at chronic inflammation sites.
- Eosinophils in inflammatory areas are exposed to high sPLA2 concentrations, suggesting a potential role in immune responses.
Purpose of the Study:
- To investigate the effects of different sPLA2 groups (IA and IIA) on human eosinophil functions.
- To elucidate the mechanisms underlying sPLA2-mediated eosinophil activation.
Main Methods:
- Isolated eosinophils from normal donors and hypereosinophilia patients were treated with sPLA2s.
- Analyzed the release of beta-glucuronidase and cytokines (IL-6, IL-8, IL-5).
- Assessed surface marker expression (CD44, CD69), mediator synthesis, and kinase activation (ERK1/2).
Main Results:
- sPLA2s induced concentration-dependent release of beta-glucuronidase, IL-6, and IL-8, with associated mRNA accumulation.
- sPLA2s increased CD44 and CD69 expression on eosinophils.
- Activation occurred independently of sPLA2 enzymatic activity and arachidonic acid generation, involving ERK1/2 pathway activation.
Conclusions:
- sPLA2s selectively activate proinflammatory and immunoregulatory functions of human eosinophils.
- The activation mechanism is independent of enzymatic activity and arachidonic acid production.
- sPLA2s represent a significant modulator of eosinophil-driven inflammation.